0
0
In a landmark development poised to transform the global fight against HIV/AIDS, the injectable drug lenacapavir—a twice-yearly HIV prevention treatment—has gained critical regulatory attention in India, a pivotal player in the decision-making for its availability across 115 nations. This innovative injectable, developed by Gilead Sciences and recently approved by the U.S. Food and Drug Administration (FDA) and endorsed by the World Health Organization (WHO), is a promising new tool that could reshape HIV prevention strategies worldwide.
Key Milestone in HIV Prevention
Lenacapavir, marketed under the brand name Yeztugo, is an HIV-1 capsid inhibitor designed as pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV infection in adults and adolescents. Unlike traditional daily pills, lenacapavir requires only two injections a year. Clinical trials show remarkable efficacy, with over 99.9% of participants remaining HIV-negative during studies such as the Phase 3 PURPOSE 1 and PURPOSE 2 trials. This long-acting formulation is particularly beneficial for people facing challenges with daily adherence or stigma around oral PrEP.
The World Health Organization released guidelines in July 2025 recommending lenacapavir as an additional prevention method, emphasizing its potential to reach populations at high risk more effectively. WHO Director-General Dr. Tedros Adhanom Ghebreyesus hailed it as “the next best thing” to an HIV vaccine, underscoring the transformative potential of this intervention as part of comprehensive prevention strategies.
India’s Crucial Regulatory Role
India’s regulatory environment now stands at a pivotal crossroads. With its vast pharmaceutical manufacturing capabilities and role as a generic drug supplier for many low- and middle-income countries, India’s approval and regulatory decisions will critically determine lenacapavir’s accessibility for 115 nations, many of which rely on generic alternatives to costly original medications.
Dr. Reddy’s Laboratories, an Indian pharmaceutical company, has partnered with global health initiatives like Unitaid, the Clinton Health Access Initiative (CHAI), and Wits Research Institute to manufacture affordable generic versions of lenacapavir, making the injectable available for as low as $40 per year in many such countries starting 2027. This price represents a monumental reduction from the $28,000 annual cost in the United States, greatly increasing the potential reach among populations where HIV remains a significant public health challenge.
India’s National AIDS Control Organisation (NACO) leads the country’s response to HIV, managing prevention and treatment programs for its estimated 2.54 million people living with HIV. Though India has made notable progress in expanding free antiretroviral treatment and controlling new infections, regulatory endorsement of lenacapavir could be a game changer, allowing for a highly effective, low-burden prevention option particularly useful in rural and high-stigma areas.
Expert Commentary and Broader Context
Carolyn Amole from CHAI described lenacapavir as a “product with real transformational potential” but stressed the importance of rapid, affordable market entry to realize this potential fully. “This injectable could change the history of HIV,” she said at the 13th International AIDS Society Conference (IAS 2025).
Despite this progress, global HIV prevention efforts face challenges. UNAIDS estimates reported 1.3 million new HIV infections in 2024, far from the 2025 target of 370,000, signaling ongoing transmission risk and the urgent need for scalable prevention options like lenacapavir.
Some experts caution that while lenacapavir represents a significant advance, it is not a vaccine and should be viewed as part of a toolbox including condoms, oral PrEP, and treatment as prevention. The high efficacy observed in trials does not eliminate the need for ongoing risk reduction strategies and comprehensive care tailored to individual needs.
Implications for Public Health and Daily Decisions
For individuals at risk of HIV, especially those facing challenges with daily oral pills or stigma, lenacapavir offers an easier, discreet option to protect themselves. From a public health perspective, making this injectable widely accessible could considerably reduce new infections, particularly in regions where maintaining daily adherence is difficult.
Indian regulators’ timely approval and facilitation of generic production will be critical to ensuring global equity in access. This role underscores India’s standing not just as a pharmaceutical hub but as a key stakeholder in global health security.
Limitations and Future Directions
While the availability of lenacapavir is a breakthrough, it is important to note it is not a vaccine and does not eliminate the necessity for other prevention measures. Further, long-term real-world effectiveness, potential side effects, and adherence in diverse settings need continued monitoring.
India’s decision will likely reverberate across the HIV prevention landscape, influencing other countries’ regulatory paths and access strategies for long-acting injectable PrEP. Success in rolling out lenacapavir could also pave the way for future innovations in HIV prevention and treatment.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
